Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Johnson and Johnson
McKesson
Merck
AstraZeneca

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,413,511

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,413,511
Title: Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
Abstract:The subject invention concerns a method of introducing at least one DNA sequence expressing a protein or protein fragment which substantially alleviates articular cartilage defects. This method involves in vitro culture of chondrocytes, transfection of the chondrocytes with a recombinant vector housing the DNA sequence to be expressed, and delivery of the transfected chondrocytes to the damaged cartilage region. This method can also be used in tandem with synovial cell delivery techniques of the present invention. This method is also useful as a model in animal studies regarding joint pathologies.
Inventor(s): Glorioso; Joseph C. (Cheswick, PA), Evans; Christopher H. (Pittsburgh, PA), Robbins; Paul D. (Pittsburgh, PA), Kane; Richard (Pittsburgh, PA)
Assignee: University of Pittsburgh of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:08/466,932
Patent Claims:1. A method of producing a polypeptide within a mammalian chondrocyte, the method comprising generating a modified chondrocyte in vitro, said modified chondrocyte comprising a heterologous polynucleotide encoding said polypeptide, operably linked to a promoter, whereby said polypeptide is produced within said modified chondrocyte, and wherein introduction of the modified chondrocyte into a joint of a mammal and production of said polypeptide inhibits cartilage degradation or promotes cartilage growth.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein said joint is associated with a full-thickness articular cartilage defect.

4. The method of claim 1, wherein said joint is a knee joint.

5. The method of claim 1, wherein said heterologous polynucleotide is introduced into said chondrocyte using a viral vector.

6. The method of claim 5, wherein said viral vector is a retroviral vector.

7. The method of claim 6, wherein said retroviral vector is MFG.

8. The method of claim 5, wherein said viral vector is an adenoviral vector.

9. The method of claim 1, wherein said heterologous polynucleotide is introduced into said chondrocyte using a non-viral vector.

10. The method of claim 9, wherein said non-viral vector is introduced into said chondrocyte using a method selected from the group consisting of liposome-mediated transfection, calcium phosphate-mediated transfection, electroporation, and DEAE-dextran mediated transfection.

11. The method of claim 1, wherein said polypeptide is TGF-.beta.1.

12. The method of claim 1, wherein said polypeptide is IRAP.

13. The method of claim 1, wherein said chondrocyte is autologous.

14. The method of claim 1, wherein said chondrocyte is introduced into a cartilage articulation within said joint using a gel solution.

15. The method of claim 14, wherein said gel is introduced into said cartilage articulation using a fixative comprising fibrinogen and thrombin.

16. The method of claim 14, wherein said gel solution comprises collagen.

17. The method of claim 1, further comprising modifing a synovial cell, said modified synovial cell comprising a heterologous polynucleotide encoding a polypeptide of interest, operably linked to a promoter; whereby said polypeptide of interest is produced within said modified synovial cell within said joint.

18. The method of claim 17, wherein said modified synovial cell is introduced into said joint by intra-articular injection.

19. The method of claim 1, wherein said polypeptide that promotes cartilage growth is selected from the group consisting of TGF-.beta..sub.1, TGF-.beta..sub.2, TGF-.beta..sub.3, TGF-.alpha., IGF-1, FGF, and BMP.

20. The method of claim 1, wherein said polypeptide that causes cartilage degradation is selected from the group consisting of IL-1.alpha., IL-1.beta., TNF-.alpha., TNF-.beta., collagenase, stromelysin, and gelatinase.

21. A method of producing an non-human mammal model of arthritis, the method comprising generating a modified chondrocyte in vitro, said modified chondrocyte comprising a heterologous polynucleotide encoding a polypeptide, operably linked to a promoter, whereby said polypeptide is produced by said modified chondrocyte, and wherein introduction of the modified chondrocyte into a joint of a mammal and production of said polypeptide causes cartilage degradation.

22. The method of claim 1, wherein said polypeptide that inhibits cartilage degradation is selected from the group consisting of IRAP, soluble IL-1 receptor, soluble TNF-.alpha. receptor, TIMP-1, TIMP-2, TIMP-3, IL-4, IL10, vIL-10, and IL-13.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Merck
Moodys
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.